RecruitingNCT06800937

Sphingolipidomic Profile in Anorexia Nervosa

Evaluation of the Sphingolipidomic Profile in Women Suffering From Anorexia Nervosa: Relationship With Clinical-endocrine and Psychiatric Parameters


Sponsor

Istituto Auxologico Italiano

Enrollment

60 participants

Start Date

Jun 19, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

: The objective of this research project will be to determine the sphingolipidomic profile in a group of women (\> 18 years) affected by Anorexia Nervosa (AN), phenotypically characterized (restricting \[AN-R\] vs binge-eating purging \[AN-BP\]). Specific questionnaires will be administered for the definition of the severity of the eating disorder and depressive state (suicidality), to which will be added the evaluation of gonadal function (i.e., plasma levels of estradiol/progesterone and use of oral contraceptives). Based on the specific lipidomic profile, which the present research project hopes to characterize, it will be possible to appropriately modify the diet of rehabilitation programs and, in the future, improve the effectiveness of the treatment itself, especially in the long term.


Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria8

  • Patients with Anorexia Nervosa:
  • Female sex
  • Age: 18 years or older
  • Diagnosis of Anorexia Nervosa in the acute phase
  • Hospitalized at the Division of Eating and Nutrition Disorders (END), San Giuseppe Hospital, Istituto Auxologico Italiano, IRCCS, Piancavallo (VB), Italy
  • Female sex
  • Age: 18 years or older
  • BMI between 18.5 and 24.9 kg/m2

Exclusion Criteria3

  • Absence of signed Informed Consent
  • Control group:
  • Absence of signed Informed Consent

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERDetermination of sphingolipidomic profile

The plasma/serum levels of the following sphingolipids will be measured: ceramides and dihydroceramides from C16 to C24, including 2 unsaturated ones (C18:1 and C24:1), sphingomyelins (those from C16 to C24 and the one C24:1), sphingosine, sphinganine, sphingosine-1-phosphate and sphinganine-1-phosphate.


Locations(1)

Istituto Auxologico Italiano IRCCS, Site Piancavallo

Oggebbio, Verbania, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06800937


Related Trials